Patent Information Affecting Seven Litigations Uncovered by Article One Partners

NEW YORK, Feb. 17 /PRNewswire/ -- Article One Partners, the world's largest patent validation firm, today announced the conclusion of seven high profile research projects, called Patent Studies, which have resulted in prior art evidence that can support a finding of patent invalidity in three litigations. Among the new results, the Article One community has discovered critical information relating to an intellectual property dispute with widespread mobile telecommunications industry impact. This EMER 911 Study concludes that prior art evidence collected could show the asserted patents to be invalid. In the event that the patents were found to be valid, they would potentially cover mobile phone services for Phase II of the Emergency 911 system.

Article One Partners (AOP) provides prior art evidence that can support invalidity conclusions for three Patent Studies: Xeloda; Hormonal Contraception; and EMER 911. The prior art was provided by 7 different AOP community members, called Advisors. Four additional Patent Studies are being closed: Doryx; Levitra; Sequenom; and Blu-Ray. Details of all the Patent Study conclusions, including named defendants, follow below.

Prior Art Evidence Found

The following Patent Studies led to discovery of prior art evidence that can support a finding of invalidity, as verified by an independent law firm.

Patent Study: EMER 911.  Article One Partners concluded its Patent Study researching the far-reaching patent assertions by EMSAT Advanced Geo-Location Technology. EMSAT asserted industry-wide patent infringement litigation in Federal Court, accusing 20 defendants, including Sprint, MetroPCS, T-Mobile and Verizon. The litigations involve infringement of four patents which potentially cover mobile phone services related to location services provided to the Emergency 911 system, used in implementing Phase II services of the E-911 service. The Article One community, as verified by an independent law firm, has uncovered new prior art evidence that can support a finding of invalidity of U.S. Patent No. 5, 946,611 and 3 related patents. The evidence results in a $50,000 reward to be shared by three winning Advisors, Skrib1, Clause8 and Anonymous.  The winning submissions disclose each of the claimed elements and teach why a person of ordinary skill in the art at the time of the invention would have been motivated to combine all of the claimed elements. For full details of the Patent Study and results, visit http://www.articleonepartners.com/winnerDetails.php?id=66.

• Defendants & Companies Impacted – Sycord Limited Partnership; Location Based Services LLC; Acacia Research Corp.; Leap Wireless International Inc.; MetroPCS Communications; Centennial Communications Corp.; Sprint Spectrum LP; Nextel Operations Inc. and all affiliated Nextel companies; Boost Mobile LLC, Boost Worldwide, Inc.; Altel Corp.; AT&T Mobility LLC; Metro PCS Communications; Metro PCS Wireless Inc.; Cricket Communications, Inc.; ETEX Telephone Cooperative Inc.; ETEX Communication LP; United States Cellular Corp.; T-Mobile USA, Inc.; Cellco Partnership d/b/a Verizon Wireless.

Patent Study: RHHBY 949 – XELODA. Hoffman-LaRoche has claimed patent infringement of U.S. Patent No. 5,472,949 by two generic drug manufacturers. The '949 Patent relates to a drug (brand name XELODA®) sold by Roche for the treatment of breast and colorectal cancer. The Article One community, as verified by an independent law firm, has uncovered new prior art evidence that can support a finding of invalidity of the '949 Patent. The evidence results in a $25,000 reward to be shared by two winning Advisors, Magnum and Top Advisor.  For full details of the Patent Study and results, visit: http://www.articleonepartners.com/winnerDetails.php?id=54)

• Defendants – Mylan Pharmaceuticals and HRL Technology Corporation.

Patent Study: WYE 814 - Hormonal Contraception.  Wyeth Pharmaceuticals has claimed patent infringement by two generic pharmaceutical companies relating to a hormonal contraception product. The Article One community, as verified by an independent law firm, has uncovered new prior art evidence that can support a finding of invalidity of Wyeth's patent (U.S. Patent No. 6,500,814). The evidence results in a $15,000 reward to be shared by two winning Advisors, Chargerpeet and Ddenim. The 2 winning submissions disclose the patented ranges as well as the continuous administration of the drug for over 110 days. For full details of the Patent Study and results, visit http://www.articleonepartners.com/winnerDetails.php?id=61.

• Defendants – Watson Pharma and Sandoz.

Additional Patent Study Closings:

Article One Advisors submitted prior art relevant to these Studies.  The Article One prior art is not conclusive about patent validity.  Advisors can continue to submit prior art to these Patent Studies and the prior art will be further considered for relevance and AOP profit sharing. The proprietary prior art collections include relevant references and are available for license. Parties interested in licensing access to the collection of relevant prior art for any Patent Study should contact Article One directly.

Patent Study: WCRX 161 - DORYX.  Warner Chilcott asserted patent infringement litigation against several generic pharmaceutical manufacturers, accusing them of infringing U.S. Patent No. 6,958,161.

• Defendants  – Impax, Mylan, Mutual United Research Laboratories, Sandoz, Actavis

Patent Study: BAYRY 178 - LEVITRA.  Bayer asserted patent infringement litigation against Teva claiming that Teva infringed U.S. Patent No. 6,362,178.

• Defendants – Teva Pharmaceuticals

Patent Study: SQNM 076.  Sequenom Inc. accused IBIS Biosciences of patent infringement of 3 patents including U.S. Patent No. 6,300,076.  IBIS Biosciences, accused of infringement, has as customers the Departments of Defense and Homeland Security, and the Center for Disease Control.

• Defendants & Companies Impacted – IBIS Biosciences, Departments of Defense and Homeland Security, and the Center for Disease Control.

Patent Study: SONY 560 – BLU-RAY.  Orinda Intellectual Properties accused Sony and Hyundai of patent infringement of U.S. Patent No. 5,438,560.  

• Defendants – Sony Corporation, Hyundai Electronic Industries

Importantly, only a U.S. federal court or the U.S. Patent Office can invalidate a U.S. patent. Article One is announcing only its own assessment based on its analysis of the prior art for purposes of determining winners to its Patent Studies. A court or the Patent Office may disagree with Article One's assessment.

About Article One Partners

Article One Partners, LLC is the world's largest patent validation firm. It employs a global human search engine in many languages to locate, identify, analyze and present previously undisclosed evidence of patent validity from anywhere in the world. The comprehensive nature and success of the Article One method is helping to legitimize the validity of all patents. Community members, our Advisors, who submit undisclosed evidence can earn up to $50,000 per research project and share in five percent (5%) of Article One's net annual profit.

Article One clients sponsor research Studies for many reasons, including to assist with patent litigation, to strengthen pending patents and to resolve other crucial patent validity issues. The result is a highly rewarded community that provides a citizen's review of patent validity. This review justifies the monopoly pricing that patents effectively confer upon their owners. It also serves to energize the U.S. patent reform movement. To learn more about Article One, or to become a member of our community, visit www.ArticleOnePartners.com.

Article One Partners and AOP are service marks of Article One Partners, LLC. All other product and company names are the trademarks and property of their respective owners. © 2010. Article One Partners, LLC. All rights reserved.

SOURCE Article One Partners, LLC